NASDAQ: LBPH - Longboard Pharmaceuticals, Inc.

Rentabilité sur six mois: +95.12%
Secteur: Healthcare

Calendrier des promotions Longboard Pharmaceuticals, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc.

plus de détails
to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

EBITDA -0.0144
EV/EBITDA 3.84
IPO date 2021-03-12
ISIN US54300N1037
Industry Biotechnology
P/BV 0.8062
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.longboardpharma.com
Цена ао 58.86
Число акций ао 0.02273 млрд
Changement de prix par jour: 0% (59.98)
Changement de prix par semaine: 0% (59.98)
Changement de prix par mois: +0.0334% (59.96)
Changement de prix sur 3 mois: +87.44% (32)
Changement de prix sur six mois: +95.12% (30.74)
Changement de prix par an: +894.69% (6.03)
Evolution du prix sur 3 ans: +903.01% (5.98)
Evolution du prix sur 5 ans: 0% (59.98)
Evolution des prix sur 10 ans: 0% (59.98)
Evolution des prix depuis le début de l'année: 0% (59.98)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 3.44 5
P/E 0 0
EV/EBITDA -2.24 0
Total: 3.13

Efficacité

Nom Signification Grade
ROA, % -107.35 0
ROE, % -132.99 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.0084 10
Total: 8

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 294.13 10
Rentabilité EPS, % 181.33 10
Total: 8
Plus de détails

Établissements Volume Partager, %
Cormorant Asset Management, LP 2353141 7
FMR, LLC 1649503 4.91
Price (T.Rowe) Associates Inc 1626982 4.84
Farallon Capital Management Llc 1560500 4.64
Polar Capital Holdings PLC 1000000 2.98
Ikarian Capital, LLC 979462 2.91
Integral Health Asset Management, LLC 900000 2.68
Blackrock Inc. 869879 2.59
Point72 Asset Management, L.P. 825000 2.45
Vanguard Group Inc 786433 2.34

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
SPDR S&P Pharmaceuticals ETF 2.34795 29.8 1.29889
iShares Neuroscience and Healthcare ETF 2.11526 19.72 0.03
Virtus LifeSci Biotech Clinical Trials ETF 1.3448 63.04 0.33
Direxion Daily Pharmaceutical & Medical Bull 3X Shares 1.2465 86.72 1.2989
iShares Micro-Cap ETF 0.27803 13.79 1.54048
Vanguard U.S. Momentum Factor ETF 0.18 27.18 1.05834
Nuveen ESG Small-Cap ETF 0.09807 9.56 1.41019
Vanguard Russell 2000 Growth ETF 0.09 17.39 0.60264
iShares Russell 2000 Growth ETF 0.08101 38.04 0.6026
iShares ESG Aware MSCI USA Small-Cap ETF 0.04743 12.78 1.49366
Vanguard Russell 2000 ETF 0.04 14.37 1.48801
ProShares UltraPro Russell2000 0.02367 89.82 1.47873
iShares Morningstar Small-Cap Value ETF 0.02069 199.14 2.50476
iShares Morningstar Small Cap Value ETF 0.02069 26.7 2.50476
iShares Morningstar Small-Cap ETF 0.01851 30.1 1.60498
iShares Morningstar Small-Cap ETF 0.01851 391.25 1.60498
Avantis U.S Small Cap Equity ETF 0.01814 27.77 1.68271
iShares Morningstar Small-Cap Growth ETF 0.01676 590.83 0.72598
iShares Morningstar Small-Cap Growth ETF 0.01676 33.63 0.72598
Fidelity MSCI Health Care Index ETF 0.01532 0.1657 1.46057
ProShares Hedge Replication ETF 0.0058 5.92 1.47892
Humankind US Stock ETF 0.00353 18.81 1.99919
iShares Russell 3000 ETF 0.00126 23.61 1.43482
Avantis U.S. Equity ETF 0.00066 20.45 1.59151
Vanguard Russell 3000 ETF 0 31.87 1.43817



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Kevin R. Lind President, CEO, Secretary & Director 1.07M 1976 (49 années)
Ms. Brandi L. Roberts CPA, M.B.A. Executive VP & CFO 662.65k 1974 (51 année)
Dr. Randall E. Kaye M.D. Executive VP & Chief Medical Officer 717.95k 1962 (63 année)
Mr. Chadwick J. Orevillo MPH Executive VP & Head of Operations N/A
Mr. Steven W. Spector J.D. Executive VP, Head of Business Development & General Counsel N/A 1965 (60 années)
Dr. Anne M. Danks Ph.D. VP & Head of Nonclinical Research & Development N/A
Mr. Gus Cardenas VP & Head of Quality Assurance N/A
Dr. Marco Peters Ph.D. VP & Head of Translational Science N/A
Dr. Dewey McLin Ph.D. VP & Head of Medical Affairs N/A
Ms. Megan E. Knight VP & Head of Investor Relations

Adresse: United States, La Jolla. CA, 4275 Executive Square - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.longboardpharma.com